Sıçanlarda D-Galaktoz ile Uyarılmış Yaşlanma Modelinde Kefir’in Beyin Dokusundaki Oksidatif Stres Üzerine Etkisi

Emel SERDAROĞLU KAŞIKÇI, Hatice Kübra GÖKALP
1.289 320

Öz


D-Galaktoz (D-GAL), oksidatif stresi arttırarak doğal yaşlanma sürecini uyaran bir monosakkarittir. Bu çalışmada, yaşlanma ile ilişkili hasarlı modelde oksidatif stres üzerine günlük kefir tüketiminin etkisi araştırıldı. Sıçanlara 8 hafta boyunca D-GAL (300 mg/kg/5 gün), Düşük doz Kefir (DKFR) (0.7 ml/kg/5 gün) ve Yüksek doz Kefir (YKFR) (3.5 ml/kg/5 gün) uygulandı. Bu süre sonunda elde edilen beyin dokusu örneklerinde Glutatyon (GSH) ve Lipid peroksidasyonu (LPO) düzeyleri ile Süperoksit dismutaz (SOD) ve Asetilkolin esteraz (AChE) aktiviteleri ölçüldü. Kontrol grubuna kıyasla D-GAL grubunda GSH düzeyleri ve SOD aktivitelerinde anlamlı bir azalma gözlendi, ancak LPO düzeyleri ve AChE aktiviteleri arttı (p <0.05). Kefirin her iki dozunda da D-GAL verilen gruba kıyasla LPO düzeyleri azaldı (p <0.05). D-GAL grubuna kıyasla, D-GAL verilen düşük doz kefir grubunda SOD aktivitesi arttı, AChE aktivitesi azaldı (p <0.05). Aynı zamanda histopatolojik bulgular da kefirin taklitçi yaşlanma modelinde koruyucu bir etki göstererek oksidatif stresi azalttığını destekledi. Bu sonuçlar kefirin özellikle beyin dokusunda yaşlanma ile uyarılmış oksidatif streste faydalı etkilere sahip olabileceğini gösterdi.


Anahtar kelimeler


D-Galaktoz; Kefir; Yaşlanma; Sıçan

Tam metin:

PDF


Referanslar


[1] Harman, D., 1972. The biologic clock: The mitochondria? Journal of the American Geriatrics Society, 20,(1972), 145-147.

[2] Amaral, S. and Ramalho-Santos, J., 2009. Aging, mitochondria and male reproductive function. Current Aging Sciences, 2, (2009), 165-173.

[3] Aoi, S. and Sakuma, K., 2011. Oxidative stress and skeletal muscle dysfunction with aging. Current Aging Sciences, 4, (2011), 101-109.

[4] Çakatay, U., 2010. Protein redox-regulation mechanisms in aging. In: Aging and Age-Related Disorders. Eds. Bondy, S. C, Maise, K., Springer Science Business Media, (2010), 1-24.

[5] Ruan, Q., Liu, F., Gao, Zhanjuan., Kong, D., Hu, X., Shi, D., Bao, Z., Yu, Z., 2013. The anti-inflamm-aging and hepatoprotective effects of huperzine A in D-galactose-treated rats. Mechanisms of Ageing and Development, (2013), http://dx.doi.org/10.1016/j.mad.2012.12.005

[6] Zhang, Z. F., Fan, S .H., Zheng, Y. L., Lu, J., Wu, D. M., Shan, Q., Hu, B., 2009. Purple sweet potato color attenuates oxidative stress and inflammatory response induced by D-galactose in mouse liver. Food and Chemical Toxicology, 47(2), (2009), 58-64.

[7] Kumar, A., Prakash, A., Dogra, S., 2010. Naringin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress induced by D-galactose in mice. Food and Chemical Toxicology, 48(2), (2010), 626-632.

[8] Kumar, A., Prakash, A., Dogra, S., 2011. Centella asiatica attenuates D-galactose-induced cognitive impairment, oxidative and mitochondrial dysfunction in mice. International Journal of Alzheimer’s Disease, (2011), doi.10.4061/2011/347569. Epub 2011 Apr 19.

[9] Lai, K., Elsas, L. J., Wierenga, K. J., 2009. Galactose toxicity in animals. International Union of Biochemistry and Molecular Biology Life, 61, (2009), 1063-1074.

[10] Zhong, S. Z., Ge, Q. H., Qu., R., Li, Q., Ma, S. P., 2009. Paeonol attenuates neuro-toxicity and ameliorates cognitive impairment induced by D-galactose in ICR mice. Journal of the Neurological Sciences, 277, (2009), 58-64.

[11] Baynes, W. J., 2001. The role of AGEs in aging: causation or correlation. Experimental Gerontology, 36, (2001), 1527-1537.

[12] Güven, M., Akman, T., Yener, A. U., Sehitoglu M. H., Yuksel, Y., Cosar, M., 2015. The neuroprotective effect of kefir on spinal cord ischemia/reperfusion injury in rats. Journal of Korean Neurosurgical Society, 57(5), (2015), 335-341.

[13] Mainville, I., Robert, N., Lee, B., Farnworth, E. R., 2006. Polyphasic characterization of the lactic acid bacteria in kefir. Systematic and Applied Microbiology, 29, (2006), 59-68.

[14] Chen, T. H., Wang, S. Y., Chen, K. N., Liu, J. R., Chen, M. J., 2009. Microbiological and chemical properties of kefir manufactured by entrapped microorganisms isolated from kefir grains. Journal of Dairy Science, 92, (2009), 3002-3013.

[15] Rodrigues, K. L., Caputo, L. R., Carvalho, J. C., Evangelista, J., Schneedorf J. M., 2005. Antimicrobial and healing activity of kefir and kefiran extract. International Journal of Antimicrobial Agents, 25, (2005), 404-408.

[16] Güzel-Seydim, Z. B., Kök-Taş, T., Greene, A. K., Seydim, A. C., 2011. Review: functional properties of kefir. Critical Reviews Food Science and Nutrition, 51, (2011), 261–268.

[17] Kanbak, G., Uzuner, K., Kuşat, O. l. K., Oğlakçı, A., Kartkaya, K., Şentürk, H., 2014. Effect of kefir and low-dose aspirin on arterial blood pressure measurements and renal apoptosis in unhypertensive rats with 4 weeks salt diet. Clinical and Experimental Hypertension, 36, (2014), 1–8.

[18] Liu, J. R., Chen, M. J., Lin, C. W., 2005. Antimutagenic and antioxidant properties of milk-kefir and soymilk-kefir. Journal of Agricultural and Food Chemistry, 53, (2005), 2467–2474.

[19] Punaro, G. R., Maciel, F. R., Rodrigues, A. M., Rogero, M. M., Bogsan, C. S., Oliveira, M. N., Ihara, S. S., Araujo, S. R., Sanches, T. R., Andrade, L. C., Higa, E. M. , 2014. Kefir administration reduced progression of renal injury in STZ-diabetic rats by lowering oxidative stress. Nitric Oxide, 37, (2014), 53–60.

[20] Beutler, E., Duron, O., Kelly, B. M., 1963. Improved method for the determination of blood glutathione. Journal of Laboratory and Clinical Medicine, 61, (1963), 882-888.

[21] Yagi, K., 1984. Assay for blood plasma or serum. Methods in Enzymology, 105, (1984), 328-331.

[22] Tsai, S. J., Yin, M. C., 2012. Anti-oxidative, anti-glycative and anti-apoptotic effects of oleanolic acid in brain of mice treated by D-galactose. European Journal of Pharmacology, 689, (2012), 81–88.

[23] Banji, D., Banji, O. J. F., Dasaroju, S., Kumar, K., 2013. Curcumin and piperine abrogate lipid and protein oxidation induced by galactose in rat brain. Brain Research, 1515, (2013), 1–11.

[24] Ho, S. C., Liu, J. H., Wu, R. Y., 2003. Establisment of the mimetic aging effect in mice caused by D-galactose. Biogerontology, 4, (2003), 15-18.

[25] Navarro, A., Gomez, C., Lopez-Cepero, J. M., Boveris, A., 2004. Beneficial effects of moderate exercise on mice aging: survival, behavior, oxidative stress, and mitochondrial electron transfer. American Journal of Physiology Regulatory Integrative and Comparative Physiology, 286(3), (2004), R505-511.

[26] Dkhar, P., Sharma, R., 2010. Effect of dimethylsulphoxide and curcumin on protein carbonyls and reactive oxygen species of cerebral hemispheres of mice as a function of age. International Journal of Developmental Neuroscience, 28, (2010), 351–357.

[27] Agostinho, P., Cunha, R. A., Oliveira, C., 2010. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease. Current Pharmaceutical Design, 16, (2010), 2766–2778.

[28] Kasapoglu, M. and Ozben, T., 2001. Alterations of antioxidant enzymes and oxidative stress markers in aging. Experimental Gerontology, 36, (2001), 209-220.

[29] Avila, J., Insausti, R., 2010. Memory and neurogenesis in aging and Alzheimer’s disease. Aging and Disease, 1(1), (2010), 30–36.

[30] Fernández, P. L., Britton, G. B., Rao, K. S., 2013. Potential immunotargets for Alzheimer’s disease treatment strategies. Journal of Alzheimers Disease, 33, (2013), 297–312.

[31] Stewart, W. F., Kawas, C., Corrada, M., Meter, E. J., 1997. Risk of Alzheimer’s disease and duration of NSAID use. Neurobiology, 48, (1997), 626–632.

[32] Aguzzi, A., Barres, B. A., Bennett, M. L., 2013. Microglia: scapegoat, saboteur, or something else? Science, 339, (2013), 156–161.

[33] Yasuhisa, A., Makiko, O., Toshiko, K., Shinya, S., Kazuyuki, U., Aruto, Y., Hiroyuki, N., 2015. Preventive effects of a fermented dairy product against Alzheimer’s disease and identification of a novel oleamide with enhanced microglial phagocytosis and anti-inflammatory activity. PLoS One, 10(3), (2015), 1-16.

[34] Çoban, J., Doğan-Ekici, I., Aydın A. F., Betül-Kalaz, E., Doğru- Abbasoğlu, S., Uysal M., 2014. Blueberry treatment decreased D- galactose-induced oxidative stress and brain damage in rats. Metabolic Brain Disease, 30, (2014), 793-802.

[35] Diniz, R. D., Gouveia, P. M. C., Pérez, B. T., Vega, C. E., Sánchez, M. L., Mancebo, D. B., Chong, D. D., Espinosa, C. I., Marcin, G. K. L, Fortes, F. C. L., 2014. Evaluation of the subchronic toxicity of kefir by oral administration in Wistar rats. Nutrition Hospital, 29(6), (2014), 1352-1359.

[36] Garrote, G. L., Abraham, A. G., De Antoni, G. L., 2001. Chemical and microbiological characterisation of kefir grains. Journal of Dairy Research, 68, (2001), 639–652.

[37] Chen, C., Chan, H. M., Kubow, S., 2007. Kefir extracts suppress in vitro proliferation of estrogen-dependent human breast cancer cells but not normal mammary epithelial cells. Journal of Medicinal Food, 10(3), (2007), 416-422.

[38] Ghoneum, M., Gimzewski, J., 2014. Apoptotic effect of a novel kefir product, PFT, on multidrug-resistant myeloid leukemia cells via a hole-piercing mechanism. International Journal of Oncology, 44, (2014), 830-837.

[39] Otles, S., Cagindi, O. E., 2003. Kefir: A probiotic dairy-composition, nutritional and therapeutic aspects. Pakistan Journal of Nutrition, 2, (2003), 54–59.

[40] Noori, N., Bangash, M. Y., Motaghinejad, M., Hosseini, P., Noudoost, B., 2014. Kefir protective effects against nicotine cessation-induced anxiety and cognition impairments in rats. Advanced Biomedical Research, 3, (2014), 251.

[41] Harvey, J. A., 2003. Role of serotonin 5-HT(2A) receptor learning. Learning & Memory, 10, (2003), 355-362.

[42] Haider, S., Khaliq, S., Haleem, D. J., 2007. Enhanced serotonergic neurotransmission in the hippocampus following typtophan administration improves learning acquisition and memory consolidation in rats. Pharmacology Reports, 59, (2007), 53-57.

[43] Özkay, Ü. D., Öztürk, Y., Can, Ö. D., 2011. Yaşlanan dünyanın hastalığı: Alzheimer hastalığı. Süleyman Demirel Üniversitesi Tıp Fakültesi Dergisi, 18(1), (2011), 35-42.

[44] Lleo, A., Greenberg, S. M., Growdon, J. H., 2006. Current pharmacotherapy for Alzheimer’s disease. Annual Review of Medicine, 57, (2006), 513-533.

[45] Friedlander, A. H., Nerman, D. C., Mahler, M. E., Norman, K. M., Yagiela, J. A., 2006. Alzheimer’s disease: psychopathology, medical management and dental implications. Journal of the American Dental Association, 137(9), (2006), 1240-1251.